

**4basebio PLC**

("4basebio" or the "Company")

**Director Dealing**

**Cambridge, UK, 30 September 2025** – 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform, announces that it was informed by Dr. Heikki Lanckriet, CEO of the Company, that on 29 September 2025 he made the following purchase in ordinary shares in the capital of the Company through the market.

Further details are set out in the Notification of Dealing Form below.

Director / PCA	Number of Ordinary Shares Acquired	Purchase Price (Aggregated) (p)	Shareholding Following Acquisition	Shareholding Following Acquisition as a Percentage of Issued Share Capital
Heikki Lanckriet	2,000	749	1,119,688	7.21%

The 2,000 additional shares purchased represent approximately 0.01 per cent. of the Company's issued share capital. The issued share capital of the Company comprises 15,538,518 ordinary shares.

**This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.**

**For further enquiries, please contact:**

**4basebio PLC** +44 (0) 1223 967 943

Dr. Heikki Lanckriet, CEO  
Nominated Adviser +44 (0) 20 7213 0880

**Cairn Financial Advisers LLP**

Jo Turner / Sandy Jamieson / Ed Downes  
Joint Broker +44 (0) 20 7653 4000

**RBC Capital Markets**

Kathryn Deegan / Matthew Coakes  
Joint Broker +44 (0) 20 7220 0500

**Cavendish Capital Markets Limited**

Geoff Nash / Nigel Birks

**Notes to Editors****About 4basebio**

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company's objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

**Forward-looking statements**

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

<b>1</b>	<b>Details of the persons discharging managerial responsibilities / person closely associated</b>	
a)	Name	Heikki Lanckriet
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/Status	Chief Executive Officer
b)	Initial notification/ Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	4basebio plc
b)	LEI	213800E2DX9EAIUNCB30
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>	
a)	Description of the financial instrument, type of instrument/identification code	Ordinary Shares  ISIN: GB00BMCLYF79

b)	Nature of the transaction	Acquisition of ordinary shares			
c)	Price(s) and volume(s)	<i>Date</i>	<i>Price(s)</i>	<i>Volume(s)</i>	
		29/09/2025	750p	1,000	
		29/09/2025	748p	1,000	
d)	Aggregated information- Â Â Â Â Â Aggregated volume- Â Â Â Â Â Aggregated Price	2,000749p			
e)	Date of transaction	29 September 2025			
f)	Place of transaction	London Stock Exchange			